The International Society for Pharmaceutical Engineering (ISPE) announced the 2021 Facility of the Year Awards (FOYA) Category Winners—including two winners of Special Recognition Awards for Operational Agility: COVID-19 Impact.
Awardees include:
Takeda Pharmaceuticals International AG (Facility Integration)
ElevateBio (Operational Excellence)
Takeda Pharmaceuticals International AG (Process Intelligence and Innovation)
Janssen Sciences Ireland (Project Execution)
Government Pharmaceutical Organization (Social Impact)
The FOYA’s judges’ panel has also awarded:
Special Recognition Awards for Operational Agility: COVID-19 Impact
Gilead Sciences, Inc.
Grand River Aseptic Manufacturing
Honorable Mentions
Biocon Biologics Limited
Locus Biosciences
Raymond G. Perelman Center for Cellular and Molecular Therapeutics
FOYA is the premier global awards program recognizing innovation and creativity in manufacturing facilities serving the pharmaceutical industry. The award-winning projects selected by the FOYA program set the standard for pharmaceutical facilities of the future by demonstrating excellence in facility design, construction, and operations.
“Now more than ever, it is important to spotlight the dedication of companies like the 2021 FOYA Category Winners who are at the forefront of setting the leadership example for the design, construction, and project execution of pharmaceutical facilities incorporating unique approaches to innovation, operability, flexibility, and key principles regarding social impact. These factors accelerate the industry’s interests to bring the next generation of transformational medicines to patients worldwide,” said Thomas Hartman, President & CEO, ISPE. “COVID-19 has certainly presented significant challenges to the pharmaceutical industry, and the innovations of these dedicated companies has a direct impact in shaping global expectations for the manufacture of effective and safe medicines.”
2021 Facility of the Year Category Awards Winners
The Facility Integration Category was awarded to Takeda Pharmaceuticals International AG for its NINLARO® The Grange Castle Factory P2 Facility in Grange Castle, Ireland. The P2 facility includes drug substance manufacture (DS), drug product (DP) blistering and secondary packaging, quality control (QC) testing, and quality assurance (QA) operations in one dedicated building. The vision for the facility was to keep it small, simple, safe, and integrated. The most novel concept of the four was the integration of the three facilities. The project exemplifies how application of good design practices and superior conceptual planning leads to excellent integration of facility and process, yielding efficient, safe, and excellent processing outcomes.
ElevateBio was awarded the Operational Excellence Category Award for its ElevateBio BaseCamp in Waltham, Massachusetts, USA. The project's goal was to tackle some of the obstacles that prevent cell and gene therapies from rapidly being available to patients. The 140,000-square-foot BaseCamp facility integrates various strategic utilization improvements to the cell and gene therapy development process. By embracing a business model that provides flexible capacity, high throughput, and process expertise while optimizing efficacy and safety, BaseCamp establishes itself as a Next Generation model for rapid therapy development and launch. ElevateBio is proving that it is possible to bring successful therapies to market faster and more efficiently than ever before.
Takeda Pharmaceuticals International AG won the Process Intelligence and Innovation Category Award for its F36 New Solid Pharmaceutical Production Building in Hikari, Japan. The strategic use of digital and automated systems in the des...
(All Rights Reserved)